Autoimmune lymphoproliferative syndrome overview: Difference between revisions
m Template |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Autoimmune lymphoproliferative syndrome''' is a form of [[lymphoproliferative disorder]]. It affects [[lymphocyte]] [[apoptosis]]. | '''Autoimmune lymphoproliferative syndrome''' is a form of [[lymphoproliferative disorder]]. It affects [[lymphocyte]] [[apoptosis]]. Autoimmune lymphoproliferative syndrome ([[ALPS]]) is a rare disorder of abnormal [[lymphocyte]] survival caused defective [[Fas]] mediated [[apoptosis]]. ALPS was first reported in 1967 by Canale and Smith; thus it was named initially as Canale and Smith syndrome. According to the 2010 revised guidelines, now [[ALPS]] is defined by the presence of [[chronic]], non-malignant, and non-infectious [[lymphadenopathy]] along with [[autoimmune]] [[cytopenias]]. ALPS was first explained in 1990 in a cohort of patients with chronic lymphoproliferation and increased numbers of double-negative T cells (DNTs). | ||
==Historical Perspective== | ==Historical Perspective== | ||
Revision as of 00:00, 27 June 2021
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome overview On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome overview |
|
Autoimmune lymphoproliferative syndrome overview in the news |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] David Teachey, MD [2]
Overview
Autoimmune lymphoproliferative syndrome is a form of lymphoproliferative disorder. It affects lymphocyte apoptosis. Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of abnormal lymphocyte survival caused defective Fas mediated apoptosis. ALPS was first reported in 1967 by Canale and Smith; thus it was named initially as Canale and Smith syndrome. According to the 2010 revised guidelines, now ALPS is defined by the presence of chronic, non-malignant, and non-infectious lymphadenopathy along with autoimmune cytopenias. ALPS was first explained in 1990 in a cohort of patients with chronic lymphoproliferation and increased numbers of double-negative T cells (DNTs).